Mipasetamab

Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC) . ADCT-601 has anti-tumor activity[1].

Product Specifications

CAS Number

[2361055-48-1]

UNSPSC

12352203

Target

ADC Antibody; TAM Receptor

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mipasetamab.html

Purity

98.26

Solubility

10 mM in DMSO

Smiles

[Mipasetamab]

Molecular Weight

(145.6 kDa)

References & Citations

[1]Zammarchi F, et al. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers. Mol Cancer Ther. 2022 Apr 1;21 (4) :582-593.